HOME >> BIOLOGY >> NEWS
New anti-inflammatory strategy for cancer therapy identified by UCSD researchers

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system's inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

The findings provide new insight into the immune system's response to inflammation, the connection between inflammation and malignancy, and how the delicate balance between cancer promotion and inhibition can be manipulated in the patient's favor, according to the study's senior author, Michael Karin, Ph.D., UCSD professor of pharmacology, American Cancer Society Research Professor, and a member of the Rebecca and John Moores UCSD Cancer Center.

The studies in mice with colon or breast cancer showed that cancer metastasis, the growth of malignant tumors beyond the original site, was halted with inhibition of either one of two naturally occurring substances, a pro-inflammatory protein called nuclear factor-kappa B (NF-kB) or an inflammatory mediator called tumor necrosis factor alpha (TNFα). The result, published in the September 20, 2004 issue of the journal Cancer Cell, was increased effectiveness of a cancer-killing protein called TNF-related apoptosis-inducing ligand (TRAIL), leading to a decrease in cancer cells and increase in the life span of tumor-bearing mice.

The study's first author, Jun-Li Luo, M.D., Ph.D., a member of the Karin team in the UCSD Laboratory of Gene Regulation and Signal Transduction, explained that normally, inflammation associated with malignancy activates NF-kB, TNFα and TRAIL, all at the same time. However, NF-kB has the upper hand, and with TNFα, stimulates tumor growth faster than TRAIL can inhibit it.

"Our results suggest that is it possible to use NF-kB or TNFα inhibitors to prevent inflammation-induced tumor growth, thus destroying their advantage, and allowing TRAIL to tip the balance in its favor,"
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
20-Sep-2004


Page: 1 2 3 4

Related biology news :

1. Anti-cancer agent built from anti-inflammatory drug
2. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
3. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
4. The anti-inflammatory effect of apoptotic bodies
5. Herb used to treat migraine headaches could be used to develop new anti-inflammatory drugs
6. MetaPhore reports general anti-inflammatory surface treatment for biomedical materials
7. Common anti-inflammatory drug rescues low-growth fetuses in mouse study
8. A novel, safer strategy for regulating gene expression
9. European common frog found to use novel mating strategy
10. Promising hospital anti-infection strategy probably wont work, study shows
11. Parasitic cowbirds thrive with a less ruthless strategy than cuckoos

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... July 18, 2019 , ... ... Meredith James, HT, PMP, to its executive team as Vice President of Operations. ... drug development. In her new role, Ms. James is responsible for ensuring on-time ...
(Date:7/17/2019)... ... 15, 2019 , ... RCH Solutions (RCH), a ... companies, announces the availability of new specialty advisory practice, a Public Cloud Managed ... emerging bio-pharma companies interested in achieving specific outcomes related to public Cloud adoption. ...
(Date:7/17/2019)... ... ... Imagine using a simple, portable test to detect cancer before malignant tissues ... South Dakota School of Mines & Technology researcher Congzhou Wang, Ph.D., these ideas are ... to monitor and prevent disease,” says Wang. , Wang, an assistant professor in ...
Breaking Biology News(10 mins):
(Date:7/26/2019)... ... July 25, 2019 , ... LeadingBiotech , an exclusive ... announces its Boston BD conference to be held on September 10, ... Boston , the event provides an opportunity for attendees to leverage insight from ...
(Date:7/17/2019)... , ... July 16, 2019 ... ... long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), ... this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space at ...
(Date:7/2/2019)... ... July 02, 2019 , ... Leading Regenerative Veterinary Medicine company, ... Where Beasts Meet Biotech. The film focuses on regenerative veterinary medicine as a ... Pharm was recently included in the Brentwood and Pacific Palisades International Film ...
(Date:6/11/2019)... ... June 10, 2019 , ... Thought Technology Ltd is ... of Biofeedback Tech Ltd as its authorised distributor for the UK ... many therapeutic treatments and clinical assessment protocols to treat stress related disorders as ...
Breaking Biology Technology:
Cached News: